KLRD1 and neoplasm: In 2005 Clarke’s group demonstrated that CA125 (that is expressed by EOC and it is used to monitor disease progression after therapeutic intervention [50]) is a potent inhibitor of NK cell-mediated cytolysis of tumor cells [44] through the downregulation of CD16 and CD94/NKG2A expression.